Investigational drug · Phase 3
Visugromab
Also called: CTL-002, Visugromab RDE, recommended expansion
Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Adult Solid Tumor, Metastatic Non-Squamous Non-Small Cell Lung Cancer, Unresectable or Metastatic Hepatocellular Carcinoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
6
5 still active
All registered trials
6
Any phase or sponsor naming "Visugromab"
First trial start
2020
Dec 9, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Visugromab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Adult Solid Tumor
- Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Unresectable or Metastatic Hepatocellular Carcinoma
- Child-Pugh A Hepatocellular Carcinoma
- Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound
- Cancer-associated Cachexia
- Solid Tumor, Adult
- Bladder Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Bladder and urothelial cancer · Liver cancer (hepatocellular carcinoma) · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "Visugromab" as an intervention, largest first.
- Visugromab in Cachexia International TrialPivotal-lookingRecruiting
CatalYm GmbHIndustry
NCT07112196 · 518 participants (planned) · Start Apr 16, 2026 · Primary completion Dec 2029
Drug: Visugromab (CTL-002); Placebo and 2 more · For: Cancer-associated Cachexia
Sites: Norwich, Connecticut; Clermont, Florida; Orange City, Florida · 79 sites in all
- First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)Active, not recruiting
CatalYm GmbHIndustry
NCT04725474 · 199 participants · Start Dec 9, 2020 · Primary completion Apr 30, 2028
Drug: visugromab (CTL-002); nivolumab · For: Solid Tumor, Adult
Sites: Essen, Germany; Frankfurt am Main, Germany; Würzburg, Germany · 13 sites in all
- Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLCPivotal-lookingRecruiting
CatalYm GmbHIndustry
NCT07246863 · 131 participants (planned) · Start Oct 7, 2025 · Primary completion Oct 1, 2029
Drug: Visugromab RDE (recommended dose for expansion); Visugromab 6mg/kg and 2 more · For: Metastatic Non-Squamous Non-Small Cell Lung Cancer; Adult Solid Tumor
Sites: Birmingham, Alabama; Los Angeles, California; Mineola, New York · 36 sites in all
- Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLCPivotal-lookingRecruiting
CatalYm GmbHIndustry
NCT07098988 · 107 participants (planned) · Start Aug 1, 2025 · Primary completion Mar 31, 2029
Drug: Visugromab; Matching placebo for visugromab and 3 more · For: Metastatic Non-Squamous Non-Small Cell Lung Cancer; Adult Solid Tumor
Sites: Birmingham, Alabama; Los Angeles, California; Derby, Connecticut · 51 sites in all
- Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 FailurePivotal-lookingRecruiting
CatalYm GmbHIndustry
NCT07219459 · 104 participants (planned) · Start Mar 19, 2026 · Primary completion Sep 2029
Drug: Visugromab RDE (recommended dose for expansion); Nivolumab and 1 more · For: Unresectable or Metastatic Hepatocellular Carcinoma; Child-Pugh A Hepatocellular Carcinoma; Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound
Sites: Irvine, California; Los Angeles, California; Orange, California · 29 sites in all
CatalYm GmbHIndustry
NCT06059547 · 31 participants · Start Sep 6, 2023 · Primary completion Oct 16, 2025
Drug: Nivolumab; Visugromab (CTL-002) and 1 more · For: Bladder Cancer; Adult Solid Tumor
Sites: Milan, Italy; Roma, Italy; Torino, Italy · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Neoadjuvant nivolumab with or without visugromab in muscle-invasive bladder cancer: the phase 2a GDFATHER-NEO trial.
Necchi A, Mercinelli C, Maiorano BA, et al. · Nat Med 2026
- Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors.
Melero I, de Miguel M, Cabanas EG, et al. · J Hematol Oncol 2026
- Decoding GDF15: Impact on prostate cancer metabolism, chemoresistance, and clinical applications.
Zhu W, Xu H, Xiong X, et al. · Chin Med J (Engl) 2026
- The Multifaceted Role of Growth Differentiation Factor 15 (GDF15): A Narrative Review from Cancer Cachexia to Target Therapy.
Filippini DM, Romaniello D, Carosi F, et al. · Biomedicines 2025
- Bexmarilimab plus azacitidine for high-risk myelodysplastic syndrome and relapsed or refractory acute myeloid leukaemia: results from the dose-escalation part of a multicentre, single-arm, phase 1/2 trial.
Kontro M, Stein AS, Pyörälä M, et al. · Lancet Haematol 2025
- Peak Team: Survey of Student Strengths and Needs and Teacher's Evaluation of an Innovative Trauma-Informed School Program.
Meurer JR, Schevers-Lumelsky P, Chelius TH, et al. · J Child Adolesc Trauma 2025
Also in development for Adult Solid Tumor
- Carboplatin AUC-5Phase 22 trials
Inhibrx Biosciences, Inc · Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.